Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tarah J. Ballinger
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
Frontiers in Oncology
Cancer Research
Oncology
Related publications
Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Geburtshilfe und Frauenheilkunde
Gynecology
Midwifery
Maternity
Obstetrics
CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?
Future Medicinal Chemistry
Drug Discovery
Molecular Medicine
Pharmacology
Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies
Clinical Cancer Research
Cancer Research
Oncology
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Targeted Therapy for HER2 Positive Breast Cancer
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer
Journal of Breast Disease
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
